Induced hypothermia fails to improve functional outcomes or survival after cardiac arrest in hospital

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-10-10 03:45 GMT   |   Update On 2022-10-10 06:51 GMT

Germany: Hypothermic temperature control after in-hospital cardiac arrest (IHCA) did not seem to improve survival or functional outcome at day 180 compared with normothermia, according to results from The HACA-IHCA (Hypothermia After In-Hospital Cardiac Arrest) trial published in Circulation."The HACA-IHCA trial was underpowered and may have been unable to detect clinically important...

Login or Register to read the full article

Germany: Hypothermic temperature control after in-hospital cardiac arrest (IHCA) did not seem to improve survival or functional outcome at day 180 compared with normothermia, according to results from The HACA-IHCA (Hypothermia After In-Hospital Cardiac Arrest) trial published in Circulation.

"The HACA-IHCA trial was underpowered and may have been unable to detect clinically important differences between hypothermic temperature control and normothermia," Kevin Roedl, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, and colleagues wrote in their study.

The study was undertaken to determine the effect of hypothermic temperature control following an in-hospital cardiac arrest on functional outcome and death versus normothermia. The HACA-IHCA was an open-label, investigator-initiated, multicenter, blinded-outcome-assessor, and randomized controlled trial that compared hypothermic temperature control (32-34°C) for 24 h versus normothermia following cardiac arrest in 11 hospitals in Germany.

All-cause mortality after 180 days was the stud's primary endpoint. Secondary endpoints were favorable functional outcomes and in-hospital mortality using the Cerebral Performance Category scale after 180 days; a score of 1 or 2 was defined as a favorable functional outcome.

Screening of 1055 patients was done for eligibility and randomization of 249 patients: 126 were given hypothermic temperature control and 123 to hypothermia. The mean age was 72.6 years, 64% were males, 73% of cardiac arrests were seen, 25% had an initial shockable rhythm, and the time to return spontaneous Circulation was 16.4±10.5 minutes.

The study led to the following findings:

  • In the hypothermic group, the target temperature was reached within 4.1 hours after IHCA, and in the normothermic group, the temperature was controlled for 48 hours at 37.0°±0.9°C.
  • Mortality by day 180 was 72.5% in the hypothermic temperature control arm, compared with 71.2% in the normothermia group (relative risk, 1.03).
  • In-hospital mortality was 62.5% in the hypothermic temperature control compared to 57.6% in the normothermia group (relative risk, 1.11).
  • In the hypothermic temperature control, the favorable functional outcome (Cerebral Performance Category 1 or 2) by day 180 was 22.5% compared with 23.7% in the normothermia group (relative risk, 1.04).
  • The study was terminated prematurely because of futility.

"Neither survival nor functional outcome improved at day 180 in patients presenting with coma after IHCA with hypothermic temperature control versus normothermia," the researchers wrote in their study.

The HACA-IHCA (Hypothermia After In-Hospital Cardiac Arrest) trial was underpowered and may not have been able to detect clinically meaningful differences between hypothermic temperature control and normothermia.

Reference:

Wolfrum S, Roedl K, Hanebutte A, Pfeifer R, Kurowski V, Riessen R, Daubmann A, Braune S, Söffker G, Bibiza-Freiwald E, Wegscheider K, Schunkert H, Thiele H, Kluge S. Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial. Circulation. 2022 Sep 28:101161CIRCULATIONAHA122060106. doi: 10.1161/CIRCULATIONAHA.122.060106. Epub ahead of print. PMID: 36168956.


Tags:    
Article Source : Circulation

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News